Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease

International Journal of Geriatric Psychiatry

Volumn 24, Issue 5, 2009, Pages 479-488

  Feldman, Howard H ^a   Pirttila, Tuula ^b   Dartigues, Jean François ^c   Everitt, Brian ^d   van Baelen, Bart ^e   Schwalen, Susanne ^f   Kavanagh, Shane ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e SGS Medisearch International NV   (Belgium)

^f UNIVERSITY OF WITTEN HERDECKE   (Germany)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Galantamine; Nursing home placement

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER SUPPORT; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISABILITY ASSESSMENT IN DEMENTIA; FEMALE; HUMAN; INSTITUTIONAL CARE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NURSING HOME; RESIDENTIAL AREA; RISK FACTOR; TREATMENT DURATION;

AGED; ALZHEIMER DISEASE; CEREBROVASCULAR DISORDERS; CHOLINESTERASE INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GALANTAMINE; HUMANS; INSTITUTIONALIZATION; LONG-TERM CARE; MALE; NURSING HOMES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 67649364065     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2141     Document Type: Article

References (31)

1. Auchus AP, Brashear HR, Salloway S, et al. 2007. Galantamine treatment of vascular dementia: a randomized trial. Neurology 69(5): 448-458.
2. Brodaty H, Corey-Bloom J, Potocnik FC, et al. 2005. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 20(2-3): 120-132.
3. Courtney C, Farrell D, Gray R, et al. 2004. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363: 2105-2115.
4. Cummings JL, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory (NPI). Neurology 44: 2308-2314.
5. Doody R, Stevens J, Beck C, et al. 2001. Practice parameter: management of dementia (an evidence-based review). Neurology 56(9): 1154-1166.
6. Doody RS. 2003. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry 64(Suppl 9): 11-17.
7. Erkinjuntti T, Kurz A, Gauthier SG, et al. 2002. Efficacy of galantmine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359: 1283-1290.
8. Feldman H, Levy AR, Hsiung G-Y, et al. for the ACCORD Study Group. 2003. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology 22: 265-274.
9. Feldman H, Van Baelen B, Kavanagh S. 2004. Galantamine delays admission to nursing home. Neurobiol Aging 25(S1): S9.
10. Feldman HH, Schmitt FA, Olin JT. 2006. Activities of daily living in moderate to severe Alzheimer's disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 20(4): 263-268.
11. Feldman HH, Pirttila T, Dartigues JF, et al. 2008. Analyses of mortality risk in dementia patients treated with galantamine. Acta Neurol Scand, in press.
12. Folstein MF, Folstein S, McHugh PR. 1975. 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
13. Geldmacher DS, Provenzano G, McRae T, et al. 2003. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 51(7): 937-944.
14. Gelinas I, Gauthier L, McIntyre M, Gauthier S. 1999. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 53: 471-481.
15. Heyman A, Peterson B, Fillenbaum G, Pieper C. 1997. Predictors of time to institutionalization of patients with Alzheimer's disease: the CERAD experience, part XVII. Neurology 48(5): 1304-1309.
16. Knopman DS, Schneider LS, Davis KL, et al., Tacrine Study Group. 1996. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 47: 166-177.
17. Lopez OL, Becker JT, Saxton J, et al. 2005. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 53(1): 83-87.
18. Lopez OL, Becker JT, Wisniewski S, et al. 2002. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 72(3): 310-314.
19. Loy C, Schneider L. 2006. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev (1): CD001747.
20. McKhann G, Drachman DA, Folstein M, et al. 1984. Clinical diagnosis of Alzheimer's disease - report of the the NINCD-SADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944.
21. Opit LJ, Pahl J. 1993. Institutional care for elderly people: can we predict admissions? Res Policy Planning 10: 2-5.
22. Ostbye T, Crosse E. 1994. Net economic costs of dementia in Canada. CMAJ 151(10): 1457-1464.
23. Raskind MA, Peskind ER, Truyen L, et al. 2004. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 61: 252-256.
24. Rockwood K, Mintzer J, Truyen L, et al. 2001. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 71(5): 589-595.
25. Rosen WG, Mohs RC, Davis KL. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry 141(11): 1356-1364.
26. Rosenbaum PR, Rubin DB. 1983. The central role of the propensity score in observational studies for causal effects. Biometrika 70(1): 41-55.
27. Tariot P, Solomon P, Morris J, et al. 2000. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54: 2269-2276.
28. Wilcock G, Howe I, Coles H, et al. 2003. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20(10): 777-789.
29. Wilcock GK, Lilienfeld S, Gaens E. 2000. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 321(7274): 1445-1449.
30. Wilkinson D, Murray J. 2001. Galantamine: a randomized, doubleblind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 16(9): 852-857.
31. Yaffe K, Fox P, Newcomer R, et al. 2002. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 287(16): 2090-2097.